Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Gastroenterol Hepatol ; 39(3): 489-495, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38095156

ABSTRACT

BACKGROUND AND AIM: While European Society of Pediatric Gastroenterology Hepatology and Nutrition advocates a no-biopsy pathway for the diagnosis of celiac disease (CeD) in children if IgA anti-tissue transglutaminase antibody (anti-tTG ab) titer is ≥10-fold upper limit of normal (ULN) and have a positive IgA anti-endomysial antibody (EMA); the data for anti-tTG Ab titer-based diagnosis of CeD in adults is still emerging. We planned to validate if IgA anti-tTG Ab titer ≥10-fold predicts villous abnormalities of modified Marsh grade ≥2 in Asian adult patients with CeD. METHODS: We recruited 937 adult patients with positive anti-tTG Ab from two databases, including AIIMS Celiac Clinic and Indian National Biorepository. The diagnosis of definite CeD was made on the basis of a positive anti-tTG Ab and the presence of villous abnormalities of modified Marsh grade ≥2. RESULTS: Of 937 adult patients with positive anti-tTG Ab, 889 (91.2%) showed villous abnormalities of modified Marsh grade ≥2. Only 47.6% of 889 adults with CeD had anti- tTG Ab titers of ≥10-fold. The positive predictive value (PPV) and specificity of anti tTG Ab titer ≥10-fold for predicting modified Marsh grade ≥2 were 99.8% and 98%, respectively. At anti-tTG Ab titer ≥11-fold, specificity and PPV were 100% for predicting villous abnormalities of modified Marsh grade ≥2. CONCLUSIONS: Approximately 50% of adults with CeD may benefit from the no biopsy pathway, reducing the health burden and risks of gastroscopy/anesthesia.


Subject(s)
Celiac Disease , Adult , Humans , Autoantibodies , Celiac Disease/pathology , GTP-Binding Proteins , Immunoglobulin A , Protein Glutamine gamma Glutamyltransferase 2 , Retrospective Studies , Sensitivity and Specificity , Transglutaminases
2.
J Gastroenterol Hepatol ; 39(2): 256-263, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37963456

ABSTRACT

BACKGROUND AND AIM: Celiac disease (CeD) has now become a global disease with a worldwide prevalence of 0.67%. Despite being a common disease, CeD is often not diagnosed and there is a significant delay in its diagnosis. We reviewed the impact of the delay in the diagnosis on the severity of manifestations of CeD. METHODS: We reviewed clinical records of 726 consecutive patients with CeD from the Celiac Clinic database and the National Celiac Disease Consortium database. We extracted specific data including the demographics, symptoms at presentation, time of onset of symptoms, time to diagnosis from the onset of the symptoms, and relevant clinical data including fold-rise in anti-tissue transglutaminase antibody (IgA anti-tTG Ab) and severity of villous and crypt abnormalities as assessed using modified Marsh classification. RESULTS: The median duration between the onset of symptoms and the diagnosis of CeD was 27 months (interquartile range 12-60 months). A longer delay in the diagnosis of CeD from the onset of symptoms was associated with lower height for age, lower hemoglobin, higher fold rise in IgA Anti tTG titers, and higher severity of villous and crypt abnormalities. About 18% of patients presented with predominantly non-gastrointestinal complaints and had a longer delay in the diagnosis of CeD. CONCLUSIONS: There is a significant delay in the diagnosis of CeD since the onset of its symptoms. The severity of celiac disease increases with increasing delay in its diagnosis. There is a need to keep a low threshold for the diagnosis of CeD in appropriate clinical settings.


Subject(s)
Celiac Disease , Humans , Celiac Disease/diagnosis , Celiac Disease/epidemiology , Celiac Disease/complications , Transglutaminases , Hemoglobins , Immunoglobulin A , Atrophy , Autoantibodies
3.
J Clin Exp Hepatol ; 13(1): 37-47, 2023.
Article in English | MEDLINE | ID: mdl-36647411

ABSTRACT

Background: Nonalcoholic fatty liver disease (NAFLD) is the commonest type of liver disease worldwide. We aimed to assess the incidence and predictors of liver-related events (LREs) and mortality in NAFLD patients. Methods: NAFLD patients (n = 957) evaluated between January 2000 and November 2021 were included. Patients were categorised as noncirrhosis (NC), compensated cirrhosis (CC) and decompensated cirrhosis (DC), and the incidence of LRE and mortality were estimated and compared. Results: The proportions of NC, CC and DC were 87.8% (n = 840), 8.8% (n = 84) and 3.4% (n = 33), respectively. The median follow-up duration was 3.9 (3.0-5.7) years, and the total cumulative duration was 4633 person-years. The incidence of LRE per 100 person-years was 0.14, 2.72 and 10.24 in patients with NC, CC and DC, respectively. The incidence of mortality was 0.12, 1.05 and 4.24 per 100 person-years, respectively, in the 3 groups. The causes of mortality in the 3 groups were liver related in 1/5 (20%), 3/4 (75%) and 6/9 (66.7%), respectively. Overall, the mortality rate was higher in those with diabetes than those without diabetes (log-rank P value = 0.005). On further analysis, diabetes was associated with poor outcomes only in NC group (log-rank P value = 0.036), and not in CC (log-rank P value = 0.353) or DC groups (log-rank P value = 0.771). On multivariate Cox proportional hazard analysis, age (hazard ratio [HR] 1.070), hypertension (HR 4.361) and DC (HR 15.036) were independent predictors of poor outcomes. Liver stiffness measurement, bilirubin, CC and DC were independent predictors of LRE. Conclusion: In our study of NAFLD from India, the incidence of LRE was found to be similar to that seen in Western studies. In NC NAFLD, diabetes was associated with poor outcomes.

4.
Neurol India ; 67(3): 772-776, 2019.
Article in English | MEDLINE | ID: mdl-31347553

ABSTRACT

BACKGROUND: Intracranial pressure (ICP) can be raised in many neurological conditions and must be treated early to prevent poor clinical outcomes. To detect the rising ICP, it is important to measure it repeatedly using a tool that is noninvasive, safe, accurate, and portable with minimal inter- and intraobserver variability. The aim of our study was to correlate cerebrospinal fluid (CSF) pressure with ultrasound (US)-measured optic nerve sheath diameter (ONSD) and find out a measurement which correlates best with CSF pressure of >20 cm of water. MATERIALS AND METHODS: All patients in whom lumbar puncture (LP) was indicated and CSF pressure could be measured using manometer were included in the study. Ocular US was used to measure the ONSD. RESULTS: A hundred patients were included in the study out of which 81% were males. The mean age was 60.5 years (±15.6) with a range of 26-90 years. Significant positive correlation was found between the ONSD and CSF pressure. Correlation coefficient (r) was 0.715 (P < 0.001). Receiver's operating characteristic curve was used to find out the ONSD value correlating with a CSF pressure of >20 cm of water. An ONSD >0.63 cm had a sensitivity of 77.3% [95% confidence interval (CI) 54.6-92.1] and specificity of 92.3% (95% CI 84.0-97.1) in predicting a CSF pressure of >20 cm of water (likelihood ratio [LR] + 10.05, LR - 0.25). CONCLUSION: There is a positive correlation of US-measured ONSD and LP-measured CSF pressure. ONSD of >0.63 cm suggests a CSF pressure of >20 cm of water.


Subject(s)
Intracranial Hypertension/cerebrospinal fluid , Intracranial Hypertension/diagnostic imaging , Intracranial Pressure , Optic Nerve/diagnostic imaging , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Manometry , Middle Aged , Optic Nerve/pathology , Prospective Studies , Reproducibility of Results , Sensitivity and Specificity , Spinal Puncture , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...